Business Wire

RELEX-SOLUTIONS

3.1.2024 09:31:35 CET | Business Wire | Press release

Share
RELEX Solutions Acquires Optimity for Unified Upstream Supply Chain Planning and Optimization Capabilities

Today, RELEX Solutions, provider of unified supply chain and retail planning solutions, announced it has acquired Optimity, a supply chain planning and optimization provider. The acquisition will bolster the RELEX retail and supply chain platform with daily production planning, optimization and production scheduling capabilities which are crucial for the end-to-end consumer goods value chain.

“The consumer goods industry is incredibly dynamic and complex. Acquiring Optimity will seamlessly link downstream demand with upstream planning, so consumer goods companies can more accurately predict consumer demand, optimize production plans and schedules, adjust inventory levels, and respond quickly to market changes or unexpected disruptions,” said Mikko Kärkkäinen, co-founder and group CEO, RELEX. “This acquisition also further accelerates our vision towards an adaptive, autonomous and synchronized supply chain unifying demand and supply planning decisions in one platform to minimize all wasted cost and product. We warmly welcome the Optimity team to RELEX.”

Optimity, with global headquarters in Sweden and offices around the world, offers a broad supply chain planning and optimization solution specifically for manufacturers and distributors. Optimity enables customers to make optimal supply chain decisions from strategic levels to detailed production scheduling. Their offerings include demand planning, production planning and scheduling, supply planning, distribution planning, inventory optimization, and S&OP. With 80+ customers across the food and beverage, and complex manufacturing industries, Optimity’s experience augments RELEX’s expertise across retail and consumer goods markets.

The acquisition brings together a highly complementary offering between the two organizations, enabling RELEX to extend and deepen its production planning and supply chain optimization capabilities, such as synchronized daily production planning, optimization and scheduling in the food & beverage and manufacturing sector.

New or expanded capabilities within the RELEX unified retail and supply chain planning platform from Optimity include:

  • Production planning: Create optimized production plans from up-to-date forecasts to balance operational costs and flexibility while considering production restrictions, material constraints and business priorities.
  • Production scheduling: Generate and manage optimized production schedules built around constraints to reduce changeover time and bolster manufacturing efficiency.
  • Network balancing: Rectify imbalances in complex distribution networks to minimize risks, reduce costs, and boost operational efficiency.
  • Distribution planning: Gain complete distribution network visibility to make smarter, proactive decisions aligned with business objectives and customer service goals.
  • Purchase planning: Balance supply-side complexity with end-to-end visibility to pinpoint the most efficient and profitable way to fulfill demand plans and customer obligations.

“Our depth in some of the most complex consumer goods industries like bakery, ready-made meals, protein production and industrial manufacturing complements the vast understanding of consumer demand that RELEX has, based on their impressive expertise managing more than $700 billion of demand in grocery alone,” said Christer Liden, CEO, Optimity. “We are thrilled to join the RELEX team and further optimize the consumer goods value chain together.”

To learn more about the acquisition, please visit this page.

About RELEX

RELEX Solutions helps retailers and consumer brands drive profitable growth across all sales and distribution channels by maximizing customer satisfaction and minimizing operative costs. Our market-leading, unified supply chain and retail planning platform helps retailers and consumer goods companies align and optimize demand, merchandising, supply chain, and operations planning across the end-to-end value chain. We drive record-high product availability, increased sales, improved sustainability, and the best return on investment in inventory, space, workforce, and capacity. Leading brands like Dollar Tree and Family Dollar, Stokke, Rite Aid, Sprouts Farmers Market, AutoZone, and PetSmart trust RELEX to optimize their supply chain and retail planning. Go to relexsolutions.com for more.

About Optimity

For nearly two decades, Optimity has challenged the supply chain planning space. Optimity has provided companies with user-friendly yet powerful planning software to optimize even the most intricate supply chains. We believe every supply chain can maximize profits effortlessly with the right tools. Optimity delivers a comprehensive solution, covering strategic optimization to detailed production scheduling. Our expert team, boasting years of industry knowledge, ensures success in every project. Supply chain planning is pivotal for manufacturing and distribution, and Optimity excels in delivering solid solutions for complex supply chains. Our integrated planning tool ensures profitability, simplifying processes for sustainable growth.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240103171132/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces Positive CHMP Opinion for Zynyz® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)30.1.2026 15:29:00 CET | Press release

Pending the European Commission decision, Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) will be the first PD-1 immunotherapy treatment for patients with advanced squamous cell carcinoma of the anal canal (SCAC) in EuropeGlobally, the prevalence of SCAC is estimated at around 1 or 2 cases per 100,000 people, with a higher incidence in women than in men1,2,3The Committee for Medicinal Products for Human Use (CHMP) positive opinion is based on data from the Phase 3 POD1UM-303/InterAACT2 trial which showed patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment4 Incyte (Nasdaq:INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (

Mediawan to Acquire The North Road Company, Creating a New Global Independent Content Platform30.1.2026 13:32:00 CET | Press release

Mediawan, the leading independent European studio led by Pierre-Antoine Capton, co-founded by Capton, Xavier Niel and Matthieu Pigasse, today announced the signing of an agreement to acquire The North Road Company (“North Road”), the preeminent independent U.S.-based studio founded by Peter Chernin. The combination creates one of the world’s largest independent studios with major creative hubs in the five continents and capabilities spanning all genres, formats and audiences. Together, Mediawan and North Road will have a stronger ability to accelerate the development of powerful IP, foster fresh creative synergies through format adaptations and co-production opportunities, and deliver ever greater value to viewers, talent and partners worldwide. The acquisition brings together two of the most dynamic independent studios in the sector with world-class creative talent, premium IP, and the scale to deliver content at the highest level. In an industry undergoing significant consolidation,

BrightSign Powers Intelligent Signage Experiences at ISE 202630.1.2026 09:00:00 CET | Press release

The Latest Players and AI Capabilities Drive Captivating, Personalized, and Interactive Signage With more industries embracing the power of visual storytelling, BrightSign, the provider of the most advanced, capable, and trusted digital media players and operating system, will showcase the latest developments in digital signage technology at ISE 2026 in Barcelona, Spain from February 3-6, 2026. BrightSign’s latest innovations come to life at booth #4S-150 through interactive real-world demos featuring retail, QSR, transportation, and corporate use cases. Visitors can test new AI-powered object detection capabilities of BrightSign players, allowing them to pick up an object and see the content on the screen respond immediately. Booth activations will be powered by BrightSign’s reliable platform including bsn.Control, BrightSignOS™, brightAuthor connected, and its global partner ecosystem. “In today’s immersive, personalized and visual world, the stakes have never been higher for powerfu

Candela Ushers in a New Era of Aesthetic Innovation at IMCAS Paris With the Launch of the Glacē™ System30.1.2026 08:30:00 CET | Press release

Iconic Vbeam® Pro and Matrix™ Systems showcased ahead of broader commercial availability Candela, a global leader in energy-based aesthetic technologies, today announced the European launch of the Glacē™ System, a facial treatment platform that signals a bold new chapter for the company and the future of aesthetic medicine. In addition to the launch of the Glacē System, Candela will also showcase its Matrix system for radiofrequency-based skin renewal and its iconic Vbeam® Pro vascular treatment platform at IMCAS 2026. Both Matrix and VBeam Pro platforms are currently available in select EMEA markets and are expected to be comprehensively launched shortly, further strengthening Candela’s leadership in the energy-based device market. Unveiled at the IMCAS World Congress 2026, these launches underscore Candela’s continued commitment to delivering innovative, science-backed treatment solutions for high-demand patient needs. Candela leads the industry in clinical efficacy and safety, suppo

Merz Therapeutics Appoints Dan Staner as President, Region Europe30.1.2026 08:00:00 CET | Press release

Merz Therapeutics today announced the appointment of Dan Staner as President, Region Europe, effective February 1, 2026. In this role, Dan will oversee the company’s European business and drive regional growth. Dan will report directly to Merz Therapeutics Chief Executive Officer, Stefan König, and will join the Therapeutics Executive Team. His appointment reflects the company’s continued commitment to strengthening its leadership capabilities and accelerating its growth strategy across key European markets.​ “Dan brings a strong track record of building and scaling biopharmaceutical businesses across Europe,” said Stefan König, CEO of Merz Therapeutics. “His deep commercial, strategic, and regional leadership experience will be instrumental in advancing our growth ambitions, expanding patient access to our therapies, and further strengthening our presence in Europe. We are very pleased to welcome Dan to Merz Therapeutics.”​ Throughout his career, Dan has held senior leadership roles i

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye